Stallergenes Greer signs global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®

Launch of Stallergenes Greer Foundation

Positive results of EfficApsi real-world study confirm significant benefit of sublingual liquid AIT treatment on the onset and worsening of asthma in patients with allergic rhinitis

Stallergenes Greer strengthens precision medicine approach in allergen immunotherapy with Imperial College London research collaboration

First Launch of Orylmyte® in Germany, Luxemburg and Belgium

Positive outcome of European decentralised registration procedure for Stalllergernes Greer's 100 IR & 300 IR sublingual House Dust Mite allergen immunotherapy tablet

Expansion of the supply of subcutaneous products in Antony

Delisting from Euronext Paris 

Stallergenes Greer becomes a private company fully owned by interests associated with the Bertarelli family, which are advised by the Waypoint Capital Group.

Actair paediatric indication in Japan.

Two new Real-World Evidence Studies show long-term benefits of sublingual allergy immunotherapy.

Oralair US paediatric indication.

Phase III clinical trial for STAGR320 to treat house dust mite-induced allergic rhinitis achieves its primary endpoint.

Acquisition of Canadian Medic Savoure, strengthening presence in North America.

Approval of Actair for commercialization in New Zealand.

Positive top-line results of Phase III clinical trial for paediatric House Dust Mite-induced allergic rhinitis, a study conducted in Japan by Shionogi & Co. Ltd.

First real-world evidence study (as part of the BREATH program) assesses long term benefits of sublingual immunotherapy.

Launch of ACTAIR® in Australia and approval in South Korea.

Positive results achieved for STG120 Japanese Cedar Phase II study.

Shareholders approve the combination of Stallergenes and Greer Laboratories leading to the creation of the world leader in allergy immunotherapy.

Launch of ACTAIR® in Japan with Shionogi & Co., Ltd, first house dust mite (HDM) immunotherapy tablet.

Temporary suspension of production and distribution at our Antony plant, France.

ORALAIR®, a 5-grass sublingual immunotherapy tablet, receives FDA approval in the U.S. US marketing authorization for the 5 grass pollen allergen immunotherapy tablet, Oralair® granted by the Food and Drug Administration (FDA).

Greer Laboratories Inc., one of the leading US pharmaceutical companies in the field of allergen immunotherapy, and Stallergenes sign exclusive agreement for the commercialization of the 5 grass pollen allergen immunotherapy tablet, Oralair®, in the US.

USDA approves veterinary allergenic extracts for sublingual immunotherapy administration.

Launch in France and Canada of the 5-grass pollen allergen immunotherapy tablet, Oralair®. Positive clinical results for the house dust mites sublingual immunotherapy tablets.

GREER® enters into Global supply agreement with IDEXX, a leader in pet healthcare innovation.

Stallergenes and Shionogi & Co. Ltd, a leading Japanese pharmaceutical company, signed an exclusive partnership agreement for the development of 2 sublingual immunotherapy tablets in Japan: house dust mite tablets and Japanese cedar pollen tablets.

Registration of the 5-grass sublingual immunotherapy tablet, Oralair®, as a pharmaceutical specialty for adults and children in 23 European countries.

Opening of an ultra-modern production unit in Antony (Paris area) dedicated to manufacturing the active ingredient in sublingual immunotherapy tablets, leading to a tenfold increase in production capacity.

Efficacy of the 5-grass sublingual immunotherapy tablet demonstrated among children.

Positive results for a new form of Allergen immunotherapy : 5-grass sublingual allergen tablet which efficacy is demonstrated among adults.

GREER® celebrated 100 years in business, receives approval for use of GREER® cultured mites in the manufacture of extracts and, the same year, launches Aller-g-complete, Vet Serology Testing and Immunotherapy Service.

Specific and patented house dust mite culture medium established : Stalmite APF® (Animal Protein Free). The company is a pioneer and the leader in production of pharmaceutical level house dust mites.

Launch of the Skintestor OMNI™, multiple-site skin test device.

European launch of high-dose sublingual immunotherapy Staloral® allowing for a new expansion phase.

GREER® Pharmacy, a licensed specialty pharmacy for immunotherapy compounding needs, started to fill prescriptions for physicians and veterinarians.

With the purchase of DHS, Bayer Pharma’s Allergy division, the Stallergenes Group became the world’s no 2 company in its field.

Initial Public Offering on the second market of the Paris stock exchange.

Commissioning of a new fully-automated NPPs production line in Antony.

Relocation of the head office and production site to Antony (Paris area) enabling Stallergenes to acquire the equipment and infrastructure necessary for its expansion and optimizing the production of NPPs.

Pasteur Mérieux ceded control of Stallergenes to the Wendel Group (known at the time as Marine-Wendel).

Launch of Staloral® and first pharmaceutical paper given on the sublingual route at the EAACI congress (European Academy of Allergy and Clinical Immunology) recognizing Stallergenes’ major contribution to the development of sublingual immunotherapy.

Start of in-house production of house dust mites. Stallergenes becomes the leading pharmaceutical producer worldwide.

Merger with the Institut Pasteur’s allergen division, allowing Stallergenes to become a leader in allergen immunotherapy. Stallergenes and Institut Pasteur merged their manufacturing activities and began a joint allergen research project.

Launch of GREER®Pick®, a single-site skin testing device.

First NPPs (Named Patient Products) automated production line increasing the rate of production. A line continually upgraded and still advanced worldwide.

Stallergenes developed and supplied the very first oral anti-allergy immunotherapy treatment.

GREER® received FDA approval of labeling for extracts for diagnostic use only.

First standardization of biological allergens in IR (index of reactivity) dose units. The aim of standardization is to guarantee the ability to reproduce biological products.

New manufacturing facility opens in Lenoir, North Carolina.

GREER® received licenses from U.S. Department of Agriculture (USDA) for allergenic extracts for Veterinary use.

Head office established in Fresnes (Paris area) with the goal of developing activities independently.

GREER® introduced Dia-Kit, a diagnostic aid for hypersensitivity pneumonitis.

Stallergenes created in Lyon (France) by Institut Mérieux, the world leader in vaccines.

GREER® started filling name-patient sets.

GREER^® obtained Product License from the US Food and Drug Administration (FDA) for the manufacture for sale of Allergenic Extracts. Specific approvals for standardized extracts were received in subsequent years.

GREER^® was established by R.T. Greer as a collecter of source materials (i.e. : roots, herbs, pollens).